Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-177 PSMA radioligand therapy versus docetaxel in oligometastatic castration-resistant prostate cancer
IRCT20260216068882N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Apr 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of lutetium lu 177 vipivotide tetraxetan, docetaxel and prednisone in prostate cancer (PCa) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: PSA response, PSA kinetics and 5 more. Started Apr 2026; status: completed.
02
Drugs
lutetium lu 177 vipivotide tetraxetandocetaxelprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on IRCT20260216068882N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260216068882N1.